Acadia Pharmaceuticals Inc (NASDAQ: ACAD) kicked off on Tuesday, down -1.87% from the previous trading day, before settling in for the closing price of $16.61. Over the past 52 weeks, ACAD has traded in a range of $14.15-$32.59.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 27.73%. While this was happening, its average annual earnings per share was recorded 296.71%. With a float of $164.29 million, this company’s outstanding shares have now reached $166.35 million.
The extent of productivity of a business whose workforce counts for 598 workers is very important to gauge. In terms of profitability, gross margin is 91.61%, operating margin of 12.08%, and the pretax margin is 14.71%.
Acadia Pharmaceuticals Inc (ACAD) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Acadia Pharmaceuticals Inc is 1.26%, while institutional ownership is 93.77%. The most recent insider transaction that took place on Nov 19 ’24, was worth 173,630. In this transaction EVP, COO, HEAD OF COMMERCIAL of this company sold 10,329 shares at a rate of $16.81, taking the stock ownership to the 62,105 shares. Before that another transaction happened on Nov 19 ’24, when Company’s PRINCIPAL ACCOUNTING OFFICER sold 4,073 for $16.81, making the entire transaction worth $68,467. This insider now owns 19,863 shares in total.
Acadia Pharmaceuticals Inc (ACAD) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported 0.28 earnings per share (EPS), lower than consensus estimate (set at 0.31) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 296.71% per share during the next fiscal year.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Trading Performance Indicators
Take a look at Acadia Pharmaceuticals Inc’s (ACAD) current performance indicators. Last quarter, stock had a quick ratio of 2.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.92. Likewise, its price to free cash flow for the trailing twelve months is 13.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.77, a number that is poised to hit 0.23 in the next quarter and is forecasted to reach 0.76 in one year’s time.
Technical Analysis of Acadia Pharmaceuticals Inc (ACAD)
The latest stats from [Acadia Pharmaceuticals Inc, ACAD] show that its last 5-days average volume of 1.07 million was inferior to 1.66 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 51.63%. Additionally, its Average True Range was 0.58.
During the past 100 days, Acadia Pharmaceuticals Inc’s (ACAD) raw stochastic average was set at 40.64%, which indicates a significant increase from 25.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.93% in the past 14 days, which was lower than the 48.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.62, while its 200-day Moving Average is $16.97. Now, the first resistance to watch is $16.54. This is followed by the second major resistance level at $16.78. The third major resistance level sits at $16.99. If the price goes on to break the first support level at $16.10, it is likely to go to the next support level at $15.89. Assuming the price breaks the second support level, the third support level stands at $15.65.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Key Stats
The company with the Market Capitalisation of 2.71 billion has total of 166,392K Shares Outstanding. Its annual sales at the moment are 726,440 K in contrast with the sum of -61,290 K annual income. Company’s last quarter sales were recorded 250,400 K and last quarter income was 32,770 K.
